Company intelligence / Profile preview
Artax Biopharma
Cambridge, Massachusetts, United Statesartaxbiopharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Artax Biopharma’s lead candidate AX-158 has achieved clinical validation in a Phase 2a trial for mild to moderate plaque psoriasis. The study demonstrated statistically significant improvements in disease biomarkers and PASI scores with a well-tolerated safety profile—no infections or discontinuations were reported. The company’s approach modulates T cell activity without causing immunosuppression, potentially offering broad utility across multiple autoimmune indications. Additional trials are planned for atopic dermatitis and other autoimmune diseases.
- Therapeutic areas
- ImmunologyDermatologyRheumatology
- Modalities
- Small molecules (specifically oral small molecule Nck modulators)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Artax Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Artax Biopharma.